Lucid Diagnostics Inc. (ticker: LUCD) is an NASDAQ-listed clinical biotech company. DredgeCap's structured extraction of LUCD's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 late-filing signal. LUCD reported $3.20M in revenue and -$13.91M for the period ending 2025-09-30, with operating cash flow of -$12.10M. Cash and equivalents stood at $47.33M (up 226.7% year-over-year). Total assets of $34.08M exceed total liabilities of $30.08M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
LUCD Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Lucid Diagnostics Inc. (LUCD) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.